Improving Efficacy and Minimizing Safety Risks of TIL Cell Therapy by Rational Engineering of TIL
Time: 8:25 am
day: Conference Day Two
Details:
• Conventional unengineered TIL cell therapy requires the use of IL2, which is associated with T-cell exhaustion, reduced cytotoxicity, and increased immune-inhibitory regulatory T cells, thus diminishing its therapeutic potential and resulting in substantial clinical toxicity that limits the eligible patient population.
• OBX-115 engineered TIL cell therapy utilizes Obsidian’s cytoDRiVE® platform to enable regulation of functional membrane-bound IL15 by reversibly modulating protein stability, enabling a lower dose of lymphodepletion than conventional unengineered TIL cell therapy, obviating the need for IL2 administration, and providing the ability to regulate antigenreactive TIL expansion.
• In an optimized and proprietary process, OBX-115 can be successfully manufactured from core needle biopsy tumor tissue, avoids the use of IL2 for rapid expansion, and delivers an optimized cytotoxic T-cell product with a high proportion of tumor-directed clones.
• In a first-in-human study, the OBX-115 treatment regimen has produced a 50% response rate in the first 6 patients, including 2 complete responses and a partial response, without any dose-limiting toxicities or Grade 4 treatment-emergent non-hematologic toxicity.
